Drug Trial Radar · NCT01613248
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
Last checked: Nov 19, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
834
Actual
Start
Jul 1, 2012
Primary completion
Dec 1, 2012
Study completion Dec 1, 2012
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine.
Conditions
- Migraine
Interventions
MK-1602Drug
Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
Placebo-matching MK-1602Drug
Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
Rescue medicationDrug
If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours, Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-DoseTime frame: 2 hours post-dose
- Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-DoseTime frame: 2 hours post-dose
- Number of Participants With One or More Adverse Events Within 48 Hours Post-DoseTime frame: Up to 48 hours post-dose
- Number of Participants With One or More Adverse Events Within 14 Days Post-DoseTime frame: Up to 14 days post-dose
- Number of Participants Who Discontinued From Study Due to Adverse EventsTime frame: Up to 5 weeks post-dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.